PT

Dados B3 › Stocks › ESPA3

Healthcare

MPM CORPÓREOS S.A.

ESPA3 — MPM CORPÓREOS S.A.

CNPJ 26.659.061/0001-59 · listed classes: ESPA3 · CVM code 25445

Participação como sócia de sociedades empresárias que desenvolvam atividades de depilação, estética facial, capilar e corporal e a comercialização de produtos cosméticos e de cuidados corporais.As filed by the company in its registration form (FCA), reference 2026-01-01 · CVM sector: Serviços médicos

Novo Mercadolisting segment
2016founded
São Paulo · SPheadquarters
Privadocontrol
Banco Btg Pactual S.Ashare registrar
BDO Rcs Auditores Independentes - Sociedade Simples Limitadaauditor
ri.espacolaser.com.brinvestor site
R$ 0.5 mavg. daily traded value (63 sessions)

Verdict

Net margin 1.2%; ROIC 6.4%; debt 2.3x EBITDA; P/E 27.0 against 14.3 for the sector; 2025 data, with a relevant recent restatement.

Confidence flag: Incomplete or flagged snapshot

Data for fiscal year 2025, received by the CVM on 2026-03-11; 5 of the 5 core figures published; last restatement recorded in 2024.

Does the company make money?

Is it sound or indebted?

Is the share expensive or cheap relative to the sector and its own history?

Descriptive: number, numeric band and comparison with the sector, the company's own history and the whole universe. Not investment advice. JSON · how the verdict works

Follow ESPA3: get an e-mail when profit turns into loss, debt or margin change band, or the statements are restated. That is all, and you can cancel in one click. See every event already recorded for ESPA3.

Quote

R$ 7.12close of 2026-09-25 · B3 (COTAHIST), updated nightly — the price the API, the MCP and the dump serve

1m +1.3% · 12m -40.7% · YTD -31.5% · 52-week R$ 5.98–12.80

15-minute delayed quote, shown by TradingView — display only: it never enters our API, MCP or dump
Close, weekly, 5 years — adjusted for 1 corporate action · return -95.4% (-46.0% a year) · adjusted with the exchange's corporate actions checked against the priceR$ 7.12 2026-09-25
2026-06-12: 0.1x shareshigh 2021-10-01: R$ 153.40low 2026-06-19: R$ 6.102026-09-25: R$ 7.12
2021low R$ 6.10 · high R$ 153.402026

Return by window

1 month3 months1 year2 years5 years10 years
Price+1.3%+11.1%-40.7% 1×-32.2% 1×-95.8% 1×—
With dividends reinvested+1.3%+11.1%-38.4%-29.5%-95.6%—
Real, net of inflation (IPCA to 08/2026)+1.3%+11.3%-40.7%-35.4%-96.6%—
R$ 1,000 would be worthR$ 1,013R$ 1,111R$ 616R$ 705R$ 44—

Closing prices from the base up to 2026-09-25. The starting price is adjusted by the corporate actions checked against the price (the small mark says how many); a jump they do not explain leaves the window blank. Reinvestment buys more shares at the close of the ex-date, with no tax or cost; only the main ticker class. The real line divides the reinvested return by the IPCA accumulated in the window (Banco Central series 433, monthly, edge months pro rata by days); the latest month is only published around the 10th of the following month.

Corporate actions

last day with rightseventmultipliercheck
2026-06-12reverse split0.10× shareschecked against the price move

Why the price chart jumps: prices are not split-adjusted. Inferred means detected from the share count and the price, not announced in the exchange file.

Valuation

Today

R$ 257 mmarket value
close of 2026-09-25 × sharesprice × shares outstanding
R$ 865 menterprise value
+ net debt 2025market value + net debt
R$ 0.43EPS 2025
profit per sharenet income for the year ÷ shares
R$ 23.75BVPS 2025
book value per shareshareholders' equity ÷ shares
33.4P/E 12m
to 2T26today's market value ÷ net income of the last 12 months (built by identity from the quarterly filings)
0.30P/B 2T26
latest quarterly balancetoday's market value ÷ equity to controlling shareholders at quarter end
0.9%ROE 12m
to 2T26net income of the last 12 months ÷ average equity over the same 12 months
0.7%net margin 12m
to 2T26net income ÷ net revenue, both over the last 12 months
2.2P/FCO 2025
FCO R$ 116 mmarket value ÷ operating cash flow
4.1P/FCF 2025
FCF R$ 63 mmarket value ÷ (operating cash flow + capex)
36.1 mshares outstandinglatest public count, treasury excluded

Snapshot: today's close over the latest public share count. Cards marked 12m use the last four quarterly filings; the others use the 2025 annual filing. The multiples below are point-in-time: priced on the day the filing became public.

At the filing date (point-in-time)

27.0P/E 2025
price of 2026-03-11 · sector 14.3 · 5 cos. · 6th of 6price ÷ earnings per share for the year
0.5P/B 2025
price of 2026-03-11 · sector 1.7 · 5 cos. · 1st of 6price ÷ book value per share
3.9EV/EBITDA 2025
price of 2026-03-11 · sector 8.7 · 5 cos. · 1st of 6enterprise value on the filing date ÷ EBITDA for the year (other sites use trailing 12 months and today's price)
14.8%FCF yield 2025
price of 2026-03-11 · sector 8.5% · 5 cos. · 2th of 6(operating cash flow + capex) ÷ market value
1.8%ROE 2025
sector -1.3% · 14 cos. · 7th of 15net income to controlling ÷ average equity
6.4%ROIC 2025
sector 11.9% · 6 cos. · 7th of 7EBIT × (1 − effective tax rate) ÷ average invested capital (gross debt + total equity − cash − investments), goodwill included — /metodologia/roic
P/E, P/B and EV/EBITDA use the price of 2026-03-11 (R$ 1.18), the first one after the 2025 filing became public on 2026-03-11 — point-in-time, not the 31 December price.

By theme, fiscal year 2025

Valuation

P/Receita todaymarket value ÷ net revenue for the year0.24×
EV/Receita todayenterprise value ÷ net revenue0.79×
P/EBITDA todaymarket value ÷ EBITDA0.98×
P/EBIT todaymarket value ÷ EBIT1.50×
EV/EBIT todayenterprise value ÷ EBIT5.04×
Earning yield todaynet income ÷ market value (the inverse of P/E)6.1%

Debt and liquidity

Dívida líquida/PLnet debt ÷ shareholders' equity0.71×
Dívida bruta/PLshort- and long-term borrowings ÷ equity0.88×
Dívida líquida/EBITDAnet debt ÷ EBITDA for the year2.30×
PL/Ativosequity ÷ total assets0.39×
Passivos/Ativos(total assets − equity) ÷ total assets0.61×
Liquidez correntecurrent assets ÷ current liabilities1.69×

Efficiency

Margem brutagross profit ÷ net revenue34.1%
Margem EBITDAEBITDA ÷ net revenue24.1%
Margem EBITEBIT ÷ net revenue15.7%
Margem líquidanet income ÷ net revenue1.2%

Profitability

ROEnet income to controlling ÷ average equity1.8%
ROICEBIT × (1 − effective tax rate) ÷ average invested capital (gross debt + total equity − cash − investments), goodwill included6.4%
ROAnet income ÷ total assets0.6%
Giro do ativonet revenue ÷ total assets0.50×

Growth

Receita, 1 anorevenue this year ÷ previous year − 16.1%
Receita, CAGR 5 anoscompound annual growth of revenue over 5 years15.9%
Lucro, CAGR 5 anoscompound annual growth of net income over 5 years (positive at both ends only)-24.1%
EBITDA, CAGR 5 anoscompound annual growth of EBITDA over 5 years (positive at both ends only)16.0%

Standardized accounts and published indicators of the fiscal year; items marked today divide today's market value or enterprise value by an account of that year.

Indicators, year by year

Four indicators as charts and the full table below. A hollow point carries a caveat; a gap is a year without the figure — we never draw a line across a hole. In the table, the arrow opens the path from the figure down to the line in the regulator's file; a cell with ! carries a caveat; a dashed dash is a suppressed figure — hover to see why. Nothing is hidden.

Fact checklist 3 of 9

Nine objective checks with the threshold written in each line and the figure behind it. Descriptive, not a recommendation; the thresholds are ours and are declared.

ROE1.8% 2025
2019: 25.6% — pl_final_sem_media2020: 23.3%2021: 34.4%2022: -6.3%2023: -2.7%2024: 0.3%2025: 1.8%
20192025
ROIC6.4%! 2025
2019: 19.0% — capital_final_sem_media2020: 6.3% — aliq_travada_452021: 20.5%2022: 4.5% — aliq_fallback_342023: 4.5% — aliq_travada_452024: 5.4% — aliq_travada_452025: 6.4% — aliq_travada_45
20192025
Net margin1.2% 2025
2019: 10.1%2020: 11.3%2021: 25.1%2022: -5.7%2023: -2.5%2024: 0.2%2025: 1.2%
20192025
Point-in-time P/E27.0x 2025
2020: 2.2x2021: 7.9x2022: -8.2x — pl_negativo2023: -14.9x — pl_negativo2024: 104.8x2025: 27.0x
20192025

Full table

indicator2019202020212022202320242025sector
ROE ⟶25.6%!23.3%34.4%-6.3%-2.7%0.3%1.8%-1.3%
ROIC ⟶19.0%!6.3%!20.5%4.5%!4.5%!5.4%!6.4%!11.9%
ROA ⟶5.8%!4.6%9.7%-2.3%-1.1%0.1%0.6%1.2%
Gross margin ⟶55.9%45.7%40.7%36.4%37.0%33.5%34.1%30.8%
EBIT margin ⟶24.5%13.2%32.0%11.5%12.7%14.6%15.7%10.2%
Net margin ⟶10.1%11.3%25.1%-5.7%-2.5%0.2%1.2%1.7%
Revenue growth (1y) ⟶—-19.4%36.9%26.9%11.0%2.3%6.1%4.3%
Revenue growth (5y CAGR) ⟶—————9.7%15.9%13.5%
Net debt/EBITDA ⟶1.21x2.83x2.55x3.54x3.21x2.58x2.30x1.67x
Current ratio ⟶1.07x1.30x1.12x1.74x1.00x1.49x1.69x1.68x

In reais, year by year

The three statements behind the ratios — income statement, balance sheet and cash flow — in the standardized lines, consolidated as filed (or parent-only when that is what the company files). EBITDA and net debt follow the published methodology; gross debt, cash and investments and free cash flow are sums the line names spell out.

line20192020202120222023202420252T26TTM
Income statement
Net revenue (R$ bn)0.60.50.70.91.01.01.10.31.1
Cost of goods and services (R$ m)-285-283-424-577-635-685-720-178-728
Gross profit (R$ m)36223929133037234537380372
EBITDA (R$ m)218126293192222249264——
Depreciation and amortization (R$ m)59576588949992——
EBIT (operating result) (R$ m)1596922810412815017229160
Pre-tax profit (R$ m)112116183-4421936-618
Income taxes (R$ m)-47-57-4-7-27-17-231-13
Net income (R$ m)6559179-51-26213-65
Net income (controlling) (R$ m)5162180-50-23316-68
Balance sheet
Total assets (R$ bn)1.11.52.22.32.32.32.22.22.2
Current assets (R$ bn)0.50.80.91.01.01.01.01.01.0
Current liabilities (R$ m)421646761563950697607642642
Gross debt (short + long term) (R$ m)318520893919869865753813813
Cash and investments (R$ m)55164143238158224145166166
Net debt (R$ m)263356749681711641608——
Shareholders' equity (R$ m)223349721887860856856862862
Cash flow
Operating cash flow (R$ m)56109-311071119116——
Capital expenditures (R$ m)-87-52-103-60-45-29-53——
Free cash flow (FCO + capex) (R$ m)-3156-134-50259063——

The two right-hand columns come from the quarterly filing (ITR): the latest quarter alone and the last 12 months (TTM) built by the same identity as the TTM P/E. EBITDA and net debt have no quarterly series here.

The current year, quarter by quarter

As the company filed it in its interim report. The fourth quarter does not exist on its own in that filing — the closed year comes in the annual one, and we do not derive a Q4, so that a figure we computed never sits beside the figures the company reported. Filed on is the date the report became public, and the price is taken from it.

quarterrevenue (R$ m)profit (R$ m)net marginP/E TTMP/Bfiled on
2024T1!273.65.62.0%-15.20.422024-05-09
2024T2!248.91.30.5%-30.60.442024-08-08
2024T3!237.5-10.0-4.2%-17.90.442024-11-07
2025T1279.412.14.3%33.60.342025-05-07
2025T2259.22.10.8%42.50.472025-08-06
2025T3266.0-9.1-3.4%37.40.492025-11-06
2026T1288.111.94.1%22.90.422026-05-06
2026T2257.5-5.9-2.3%31.90.282026-08-11

Full series, every quarter: GET /empresas/ESPA3/trimestres

Dividends

Next: 2026-12-31 payment · dividend or interest on equity (the filing does not say) R$ 0.0006 filing to the regulator on 2026-04-29

The latest dividend by ESPA3 was a dividend of R$ 0.0006 per share (record date 2026-05-04, payment 2026-05-29). In the last 12 months: 3 payments adding up to R$ 0.0382 per share. Average yield of the last 5 full years: 2.7%.

typerecord dateex-datepaymentper share
dividend2026-05-042026-05-052026-05-29R$ 0.0006

Ex-date is the first trading session after the record date, from our own price history. Payment date comes from the exchange file; CVM marks a date taken from the filing to the regulator. Only the main ticker class.

Record dates in the last 5 years, by month: JanFebMarApr1May1JunJulAugSep2OctNovDec2

Per year

yearper sharepaymentsyield
2026R$ 0.000610.0%
2025R$ 0.039333.8%
2021R$ 0.142231.7%

Yield per year = the year's dividends over the close of its last session; the current year is partial.

Shareholders and free float

68.72%free float
24,838,680 sharesshares outstanding held by the market, as filed in the FRE
10,611shareholders
10,341 individuals · 158 companies · 112 institutionalcount at the last shareholders meeting, from the FRE
YGOR ALESSANDRO DE MOURA +4controlling shareholder
as declared in the FREshareholders the company marks as controlling
100% ONtag along (minimum)
Novo Mercadominimum guaranteed by the listing segment or by law; the bylaws may grant more
shareholdertype% ON% PN% total
UNA CAPITAL LTDA.PJ13.13%0.00%13.13%
YGOR ALESSANDRO DE MOURA ctrl agreementPF10.92%0.00%10.92%
PAULO JOSÉ IÁSZ DE MORAIS ctrl agreementPF10.01%0.00%10.01%
MFI FI MULTIMERCADO CRÉDITO PRIVADO INVESTIMENTO NO EXTERIOR ctrl agreementPJ5.57%0.00%5.57%
SMZXP Participações Ltda. ctrl agreementPJ2.55%0.00%2.55%
JOSÉ CARLOS SEMENZATO ctrlPF0.96%0.00%0.96%
Others (market)———55.97%
Treasury shares———0.89%

Direct holdings from the reference form (FRE) filed on 2026-09-14, version 6. The chain of control (who owns the holding) is not reproduced here. Names of individuals appear as in the public filing.

Filings and notices

filedcategorysubjectdocument
2026-09-18Reunião da Administração · Conselho de AdministraçãoRCA - Renúncia Diretoropen
2026-09-18Comunicado ao Mercado · Outros Comunicados Não Considerados Fatos RelevantesComunicado ao Mercado - Renúncia Diretoropen
2026-09-09Valores Mobiliários negociados e detidos (art. 11 da Instr. CVM nº 358) · Posição Consolidada—open
2026-09-09Valores Mobiliários negociados e detidos (art. 11 da Instr. CVM nº 358) · Posição Individual - Cia, Controladas e Coligadas—open
2026-08-12Comunicado ao Mercado · Apresentações a analistas/agentes do mercadoApresentação de Resultados 2T26open
2026-08-12Comunicado ao Mercado · Apresentações a analistas/agentes do mercadoApresentação de Resultados 2T25 - Versão Inglêsopen
2026-08-12Reunião da Administração · Conselho de AdministraçãoRCA- Renúncia Diretor Financeiro e de Relações com Investidoresopen
2026-08-12Fato RelevanteFato Relevante - Renúncia Diretor Financeiro e de Relações com Investidoresopen
2026-08-11Dados Econômico-Financeiros · Press-releaseRelease de Resultados 2T26open
2026-08-11Dados Econômico-Financeiros · Press-releaseApresentação de Resultados 2T25 - Versão Inglêsopen

The last filings this company sent to the CVM outside its financial statements, newest first, from the regulator's own IPE index. The subject line is the company's own free text. We do not summarise or classify these documents — read the original.

Piotroski F-Score 8/9 (2025) — what each criterion means.

Restated filings for this company

The regulator overwrites the old version; we keep both. Figures in R$ millions: first filing on the left, restatement on the right.

fiscal yearaccountfirst filingrestated
2021BPA 1.01851.4867.8
2022DRE 3.02-576.5-588.5
2022DRE 3.03330.0318.0
2024DFC_MI 6.01118.7112.3
2021BPP 2.03.094.58.9
2023DFC_MI 6.0170.574.4
2021DRE 3.05228.5224.8
2021DRE 3.07183.4179.6

Every restatement of this company, year by year

This company appears in

Compare

Side by side, with each figure's caveat and how often each company restated its filings.

ESPA3 × RDOR3 · ESPA3 × DASA3 · ESPA3 × HAPV3 · ESPA3 × HYPE3 · ESPA3 × NATU3 · ESPA3 × FLRY3

compare with the sector: RDOR3 × SAUD3 × FLRY3

Other companies in Healthcare

15 more with a page, same CVM sector — a classification of the regulator's, not ours.

Take this into your code

Everything on this page is also JSON: GET /empresas/ESPA3/indicadores. WEGE3 is open for testing without a key; for the rest, create a free key (200 calls/day, no card).

Price coverage: 1,411 sessions, 2021-02-01 → 2026-09-25 · methodology · how we verify

Sources: CVM (open data, ODbL) and B3 (COTAHIST). Not affiliated with B3 or the CVM. Not investment advice.

Numbers on this page are live. Data version 2026-09-27-reapresentacao-agreg · page generated 2026-09-27 07:18 UTC. If this does not match /saude, you are reading a cached copy.